Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 18/20 | 1.00 |
| ▸ | CDK7 | P50613 | 17/20 | 1.00 |
| ▸ | CDK1 | P06493 | 16/20 | 1.00 |
| ▸ | CCNE1 | P24864 | 15/20 | 1.00 |
| ▸ | CCNH | P51946 | 14/20 | 1.00 |
| ▸ | CDK4 | P11802 | 13/20 | 1.00 |
| ▸ | CCND1 | P24385 | 13/20 | 1.00 |
| ▸ | CCNB1 | P14635 | 12/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 7/20 | 0.83 |
| ▸ | CDK5 | Q00535 | 5/20 | 0.82 |
| ▸ | CDK9 | P50750 | 4/20 | 0.82 |
| ▸ | TP53 | P04637 | 1/20 | 0.70 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.70 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.70 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.70 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.70 |
| ▸ | TSHR | P16473 | 1/20 | 0.70 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.70 |
| ▸ | RAB9A | P51151 | 1/20 | 0.70 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4488384 | 1.00 | CDK2 (1.00) | CDK2CDK7CDK1CCNE1CCNH | |
| SCHEMBL4484946 | 0.91 | CDK2 (1.00) | CDK2CDK7CDK1CCNE1CCNH | |
| SCHEMBL4487926 | 0.91 | CDK2 (1.00) | CDK2CDK7CDK1CCNE1CCNH | |
| SCHEMBL13633351 | 0.91 | CDK2 (1.00) | CDK2CDK7CDK1CCNE1CCNH | |
| SCHEMBL6244174 | 0.91 | CDK2 (1.00) | CDK2CDK7CDK1CCNE1CCNH | |
| SCHEMBL6246011 | 0.91 | CDK2 (1.00) | CDK2CDK7CDK1CCNE1CCNH | |
| SCHEMBL6248828 | 0.91 | CDK2 (1.00) | CDK2CDK7CDK1CCNE1CCNH | |
| SCHEMBL3879278 | 0.91 | CDK2 (1.00) | CDK2CDK7CDK1CCNE1CCNH | |
| SCHEMBL3944585 | 0.90 | CDK2 (1.00) | CDK2CDK7CDK1CCNE1CCNH | |
| SCHEMBL1379184 | 0.90 | CDK2 (1.00) | CDK2CDK7CDK1CCNE1CCNH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7612079-B2 | 2,6,9-substituted purine derivatives and their use in the treatment of proliferative disorders | CYCLACEL LIMITED (GB) | 2009-11-03 | — | — | US | disclosed |
| US-7612079-B2 | 2,6,9-substituted purine derivatives and their use in the treatment of proliferative disorders | CYCLACEL LIMITED (GB) | 2009-11-03 | — | — | US | disclosed |
| US-7612079-B2 | 2,6,9-substituted purine derivatives and their use in the treatment of proliferative disorders | CYCLACEL LIMITED (GB) | 2009-11-03 | — | — | US | disclosed |
| WO-2007110649-A2 | PROCESS FOR THE PREPARATION OF 2,6,9-TRISUBSTITUTED PURINES | CYCLACEL LIMITED (GB) | 2007-10-04 | — | — | WO | disclosed |
| EP-1399446-B1 | 2,6,9-SUBSTITUTED PURINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF PROLIFERATIVE DISORDERS | CYCLACEL LTD (GB) | 2005-08-03 | — | — | EP | disclosed |
| US-20050009846-A1 | 2,6,9-Substituted purine derivatives and their use in the treatment of proliferative disorders | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2005-01-13 | — | — | US | disclosed |
| EP-1399446-A1 | 2,6,9-SUBSTITUTED PURINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF PROLIFERATIVE DISORDERS | Cyclacel Limited (GB) | 2004-03-24 | — | — | EP | disclosed |
| WO-2003002565-A1 | 2,6,9-SUBSTITUTED PURINE DERIVATIVES AND THEIR USE N THE TREATMENT OF PROLIFERATIVE DISORDERS | CYCLACEL LIMITED (GB) | 2003-01-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009846-A1 | 2,6,9-Substituted purine derivatives and their use in the treatment of proliferative disorders | TYMP, PNP, IMPDH1 | CDK2 40/4885CDK7 93/4885CDK1 117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.